Free Trial
NASDAQ:SBTX

Silverback Therapeutics (SBTX) Stock Price, News & Analysis

Silverback Therapeutics logo
$17.65 -0.33 (-1.84%)
As of 08/7/2025

About Silverback Therapeutics Stock (NASDAQ:SBTX)

Key Stats

Today's Range
$17.34
$18.00
50-Day Range
$13.44
$18.35
52-Week Range
$2.80
$8.97
Volume
741,288 shs
Average Volume
337,931 shs
Market Capitalization
$636.42 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive SBTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Silverback Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SBTX Stock News Headlines

ARS Pharmaceuticals Inc (SPRY)
SPRY ARS Pharmaceuticals, Inc.
Musk’s Project Colossus could mint millionaires
I predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new millionaires than any tech advance in history. And for a limited time, you have the chance to claim a stake in this project, even though it’s housed inside Elon’s private company, xAI.
See More Headlines

SBTX Stock Analysis - Frequently Asked Questions

Silverback Therapeutics' stock was trading at $10.55 at the start of the year. Since then, SBTX stock has increased by 67.3% and is now trading at $17.65.

Silverback Therapeutics, Inc. (NASDAQ:SBTX) posted its quarterly earnings results on Wednesday, November, 10th. The company reported ($0.65) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.65).

Silverback Therapeutics (SBTX) raised $126 million in an IPO on Friday, December 4th 2020. The company issued 7,000,000 shares at $17.00-$19.00 per share. Goldman Sachs, SVB Leerink and Stifel acted as the underwriters for the IPO and H.C. Wainwright was co-manager.

Shares of SBTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Silverback Therapeutics investors own include Athenex (ATNX), AbbVie (ABBV), Applied Materials (AMAT), JPMorgan Chase & Co. (JPM), Luminar Technologies (LAZR), Lineage Cell Therapeutics (LCTX) and Aviat Networks (AVNW).

Company Calendar

Last Earnings
11/10/2021
Today
8/09/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:SBTX
CIK
1671858
Fax
N/A
Employees
83
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($2.42)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$89.48 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-29.62%
Return on Assets
-28.20%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
67.87
Quick Ratio
67.87

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$7.41 per share
Price / Book
2.38

Miscellaneous

Outstanding Shares
36,058,000
Free Float
23,654,000
Market Cap
$636.42 million
Optionable
Not Optionable
Beta
0.60

Social Links

Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

This page (NASDAQ:SBTX) was last updated on 8/9/2025 by MarketBeat.com Staff
From Our Partners